Biotech hails trial results for antidepressant paired with genetic testAnonymous08/08/2025 (Fri) 16:36No.83900del
Hans Eriksson, chief medical officer of Munich-based HMNC Brain Health, called the study of its BH-200 drug in 338 patients with serious depression “a major step forward in precision psychiatry”.